30 July 2019

Bart Kiemeny is on stage in his Radboudumc cycling outfit, 3500 kilometers in his legs and surrounded by podium girls of ‘Daags na de Tour’. Because yes, professor Bart Kiemeney cycled the Tour de France. For more money on cancer research.

With over €47,000 on the counter, Kiemeney can see the Tour de France as a great success. Not only did he get close to his target amount (you can still donate!), but Bart was also one of the few to have covered the entire course of this edition of the Tour de France.

 "Now I'm really not going to cycle the Tour anymore!” the professor writes in his epilogue.
 

Bart's Tour de France

Read the entire epilogue on www.tourdefrancevanbart.nl or donate.
That's still possible!

Related news items


Rob Aarnoutse is appointed as professor in Translation pharmacology of antimicrobial agents in particular drugs for tuberculosis

25 January 2021

Hospital pharmacist and clinical pharmacologist Rob Aarnoutse is appointed as professor in ‘Translation pharmacology of antimicrobial agents, in particular drugs for tuberculosis’ at Radboud University / Radboudumc, starting 16 November 2020.

read more

Oral health research makes significant impact at the 148th WHO Executive Board meeting

25 January 2021

During the 148th session of the World Health Organization (WHO) Executive Board meeting, Member States passed a game-changing resolution on oral health. WHO Director General Dr Tedros Adhanom Ghebreyesus called it a “landmark resolution”.

read more

Radboud Young Academy safeguards the future of science

21 January 2021

New platform to provide advice on policy, create an interdisciplinary network of early career scientists, and promote career development.

read more

Increase radio- and immunotherapy efficacy by targeting hypoxia

21 January 2021

In a paper recently accepted by Clinical Cancer Research, Daan Boreel, together with Paul Span, Sandra Heskamp, Gosse Adema and Jan Bussink, reviews the therapeutic potential of decreasing the lack of oxygen (hypoxia) often found in solid tumors.

read more

Radiation boost lowers risk of prostate cancer recurrence

21 January 2021

An additional external-beam radiation dose delivered directly to the tumor can benefit the prospects of men with non-metastatic prostate cancer, without causing additional side effects. The risk of relapse within five years for these men is smaller than for men who did not receive this boost.

read more

New research through grants for Radboudumc researchers

14 January 2021

Several researchers at the Radboudumc have received grants to start new studies, including on rare diseases, liver disease and cancer metastases. These are grants from the Dutch Research Council, European Joint Programme on Rare Diseases and the Gastric Liver Disease Foundation.

read more